Microsatellite

• Microsatellites are short, tandemly repeated DNA sequences, typically 1-6 base pairs long, found across the human genome.
• They contribute to genetic diversity and are involved in gene regulation and chromatin structure.
• Types of microsatellites biology classifies them by the length of their repeating unit, such as mononucleotide, dinucleotide, or trinucleotide repeats.
• Microsatellite instability (MSI) is a condition characterized by changes in microsatellite length due to defects in DNA mismatch repair.
• MSI is a significant biomarker, particularly in oncology, guiding diagnosis, prognosis, and treatment decisions for certain cancers.

What is a Microsatellite?

A Microsatellite refers to a tract of repetitive DNA in which certain DNA motifs (ranging from one to six or more base pairs) are repeated, typically 5–50 times. These sequences are ubiquitous in eukaryotic genomes, including humans, and are often found in non-coding regions, though they can also occur within genes. Their highly polymorphic nature, meaning they vary greatly in length among individuals, makes them invaluable genetic markers for various applications, from forensic science to disease mapping.

The precise number of repeats at a given microsatellite locus can differ significantly between individuals, making them powerful tools for distinguishing genetic profiles. This variability arises primarily from errors during DNA replication, specifically “slippage” events where the DNA polymerase either adds or deletes repeat units. These changes are usually stable and heritable, contributing to the genetic diversity observed within populations.

Functions and Types of Microsatellite DNA

The microsatellite DNA function extends beyond mere genetic markers; these repetitive elements are increasingly recognized for their roles in various biological processes. They can influence gene expression by affecting transcription, translation, and chromatin structure. For instance, microsatellites located in promoter regions can modulate the binding of transcription factors, thereby regulating gene activity. They may also contribute to the structural integrity of chromosomes and play a part in evolutionary adaptation by providing a source of rapid genetic change.

Based on the length of their repeating unit, there are several types of microsatellites biology classifies. These include:

• Mononucleotide repeats: A single base pair repeated (e.g., AAAAAA).
• Dinucleotide repeats: Two base pairs repeated (e.g., CACACA).
• Trinucleotide repeats: Three base pairs repeated (e.g., CAGCAGCAG).
• Tetranucleotide repeats: Four base pairs repeated (e.g., GATAGATAGATA).
• Pentanucleotide and hexanucleotide repeats: Five or six base pairs repeated, respectively.

Trinucleotide repeats are particularly notable because their expansion within coding regions can lead to severe neurological disorders, such as Huntington’s disease and fragile X syndrome, due to the production of altered proteins.

Understanding Microsatellite Instability (MSI)

Microsatellite instability (MSI) is a molecular condition characterized by alterations in the length of microsatellite sequences. This instability arises from defects in the DNA mismatch repair (MMR) system, which is responsible for correcting errors that occur during DNA replication. When the MMR system is dysfunctional, these replication errors, particularly insertions or deletions within microsatellite regions, accumulate, leading to changes in the number of repeat units.

The microsatellite instability explanation is critical in oncology, as MSI is a hallmark of certain cancers, most notably hereditary nonpolyposis colorectal cancer (HNPCC), also known as Lynch syndrome, and a significant subset of sporadic colorectal, gastric, and endometrial cancers. Approximately 15% of all colorectal cancers exhibit MSI, according to data from the National Cancer Institute. Detecting MSI in tumors is vital for several reasons:

• Diagnosis: It can indicate a predisposition to Lynch syndrome.
• Prognosis: MSI-high (MSI-H) tumors often have a better prognosis in early-stage colorectal cancer.
• Treatment Response: MSI-H tumors show differential responses to certain chemotherapies and are particularly responsive to immune checkpoint inhibitors.

Testing for MSI has become a standard practice in the clinical management of various cancers, guiding personalized treatment strategies and improving patient outcomes.